In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

Some of the best links we picked up around the internet

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...

This week, we look at a CRISPR-based therapy for HIV that has just passed the IND approval stage, and will soon be tested in a Phase 1/2 clinical...

This week’s clinical update looks at a Phase 1 trial for ET-01, a CRISPR-edited blood cell therapy for beta thalassemia.

CRISPR-based blood cell therapies are advancing through clinical trials, with promising results stacking up for certain rare genetic diseases and some...